It is proposed to carry out embedded Electronic Systems (ES) for the supervision and characterization of cells and cell cultures, which allow to act on them by means of programmable electrostimulation signals (EST). The objective is to study, know and improve the techniques of cell differentiation towards various types of lineages and tissues of interest in regenerative medicine. The design and manufacture of systems with reduced weight and size, energy autonomous and wireless are pursued, which reduce the workload, automate experiments and monitor in real time the evolution of a cell culture based on electrical BioImpedance (BI) as a marker. It is proposed to monitor the evolution of neuroblastoma, breast cancer, lung cancer, myoblast and osteoblast cell lines, useful in regenerative therapies, tissue engineering, and cancer research, towards the conformation of the corresponding cell or tissue type, optimizing the differentiation processes through design of the adequate signals of electrical stimulation. From the results obtained in a first measurement setup, two more setups are proposed: one oriented to the clinical development of tissue engineering; and another dedicated to the study and characterization of EST processes at the cellular level, through the manufacture of microelectrode arrays (MicroElectrode Array, MEA). Taking advantage of this last setup, we propose its application in cancer studies, in two aspects: on the one hand, evaluating the effect of EST as a tumor inhibitory technique (in the N2A and SK-N-SH lines), and on the one hand, another, using MEAs for the determination of cell motility: position and velocity of tumor cells in cultures (A-549 and MCF7). In summary, monitoring SEs and ESTs measuring electrical BIs will be developed, in parallel to a cell and tissue biometry procedure for the real-time identification of the biological material differentiated or not, and its dynamic characteristics: position, trajectory and speed, with application in tissue engineering and cancer. The results will be validated using biomedical experimentation standards in the proposed cell lines.
Project PID2021-128009OB-C31 funded by MICIU / AEI / 10.13039/501100011033 / and FEDER 'Una manera de hacer Europa'.
